AEON Biopharma, Inc. (AEON)

AEON Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2023	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Jun 30, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	43.62	9.98	9.98	6.38	8.2
Depreciation & Amortization	0.07	-	-	-	-
Stock-Based Compensation	4.91	-	-	-	-
Other Adjustments	-64.57	-10.42	-10.42	-10.58	-10.14
Changes in Accounts Payable	1.24	-	-	-	-
Changes in Accrued Expenses	-1.5	1.99	1.99	1.99	0.61
Changes in Income Taxes Payable	-	-	-	0.32	0.2
Changes in Other Operating Activities	-0.26	0.92	0.92	0.92	-0.37
Operating Cash Flow	-19.84	-0.98	-0.98	-0.98	-1.49
Purchases of Investments	-	-	-	-	-276
Other Investing Activities	0.16	0.4	0.4	0.4	-
Investing Cash Flow	0.16	0.4	0.4	0.4	-276
Long-Term Debt Issued	15	0.15	0.15	0.15	0.14
Long-Term Debt Repaid	-	-	-	-	-0.07
Net Long-Term Debt Issued (Repaid)	15	0.15	0.15	0.15	0.06
Issuance of Common Stock	0.05	-	-	-	278.3
Net Common Stock Issued (Repurchased)	0.05	-	-	-	278.3
Other Financing Activities	-	-	-	-	-0.37
Financing Cash Flow	15.2	0.15	0.15	0.15	277.99
Net Cash Flow	-4.58	-0.43	-0.43	-0.43	0.5
Free Cash Flow	-19.88	-0.98	-0.98	-0.98	-1.49
Free Cash Flow Per Share	-37.44	-1.90	-0.51	-0.51	-0.00
Levered Free Cash Flow	7.59	13.04	13.04	9.75	8.7
Unlevered Free Cash Flow	39.35	-0.15	-0.15	0.31	-1.49

Updated Aug 12, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q